Search details
1.
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Blood
; 143(8): 685-696, 2024 Feb 22.
Article
in English
| MEDLINE | ID: mdl-37976456
2.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Article
in English
| MEDLINE | ID: mdl-37369099
3.
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.
Br J Haematol
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38719214
4.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37646664
5.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Eur J Nucl Med Mol Imaging
; 51(3): 749-755, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37943339
6.
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Ann Hematol
; 102(10): 2791-2801, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37552322
7.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34407608
8.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34196165
9.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32511983
10.
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
Blood
; 130(18): 2027-2031, 2017 11 02.
Article
in English
| MEDLINE | ID: mdl-28827408
11.
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
Haematologica
; 105(5): e256-e260, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32029506
12.
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Haematologica
; 100(3): 377-84, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25637055
13.
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Ann Hematol
; 93(7): 1207-14, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24526137
14.
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Clin Lymphoma Myeloma Leuk
; 24(4): e130-e137, 2024 04.
Article
in English
| MEDLINE | ID: mdl-38267355
15.
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Nuklearmedizin
; 63(2): 57-61, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38190998
16.
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
J Immunother Cancer
; 12(3)2024 Mar 21.
Article
in English
| MEDLINE | ID: mdl-38519055
17.
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.
Blood Adv
; 7(4): 555-559, 2023 02 28.
Article
in English
| MEDLINE | ID: mdl-35696759
18.
Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging.
Mol Imaging Biol
; 25(4): 758-764, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37286923
19.
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
J Nucl Med
; 64(12): 1889-1894, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37797975
20.
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.
Ann Hematol
; 91(7): 1031-7, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22286070